Form 4: Catheter Precision Director Acquires 40,000 Stock Options

Catheter Precision Director James Joseph Caruso acquired 40,000 stock options with an exercise price of $1.15, signaling potential confidence in the company's future.

Summary

• James Joseph Caruso, a Director of Catheter Precision, Inc. (VTAK), acquired 40,000 derivative securities in the form of Options (Right to Buy).
• The transaction date for these options was March 26, 2026.
• Each option has an exercise price of $1.15.
• The options vest 100% on the 180-day anniversary of the grant date, March 26, 2026.
• The expiration date for these options is March 26, 2036.
• Upon exercise, each option represents the right to acquire one share of Catheter Precision Common Stock.
• Following this transaction, Mr. Caruso beneficially owns 40,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. Insider option acquisition demonstrates management's belief in future stock appreciation, aligning their interests with shareholders, though it's not as strong a signal as direct share purchase.

Positives

• The acquisition of 40,000 stock options by a Director indicates a vote of confidence from an insider in the company's future prospects and potential stock price appreciation.
• The long expiration date of March 26, 2036, provides a significant window for the options to become in-the-money, aligning the director's long-term interests with shareholder value.

Negatives

• Options are not direct share ownership and only provide value if the stock price rises above the exercise price of $1.15.
• The options have a vesting period of 180 days, meaning they are not immediately exercisable.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider buying, such as a director acquiring stock options, is often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or poised for future growth. This type of transaction can sometimes precede positive company developments, though it is not a guarantee.

Stakeholder Impact

• Shareholders: May view this as a positive indicator of insider confidence, potentially leading to increased investor interest.
• Management/Employees: Reinforces alignment between leadership and company performance, potentially boosting morale.

Next Steps

• The options will vest 100% on the 180-day anniversary of the grant date (approximately September 22, 2026).
• Following vesting, the Director may choose to exercise the options at the $1.15 strike price at any point before the March 26, 2036 expiration date.

Key Dates

Keywords

Catheter Precision, VTAK, Insider Trading, Stock Options, Director Acquisition, Beneficial Ownership, SEC Form 4, Medical Devices